title: Comparative analysis of cardiac magnetic resonance viability indexes to predict functional recovery after successful percutaneous coronary intervention in acute myocardial infarction.
abstract: The aim of this study was to examine the relative value and the influence of the association of 4 cardiac magnetic resonance (CMR) viability indexes for predicting segmental functional recovery after optimal pharmacologic therapies and early percutaneous coronary intervention in acute myocardial infarction (AMI). CMR has been shown to predict functional recovery after AMI. The relative predictive value of CMR viability indexes remains disputed and has not been described in AMI reperfused within the first 12 hours. Sixty-nine patients with a first reperfused (<12 hours) Thrombolysis In Myocardial Infarction grade 3 AMI (61 men, 57.6 +/- 12.6 years) were studied on day 5 +/- 2. Low-dose (10 microg/kg/min) dobutamine response (DOB), microvascular obstruction (MVO), relative delayed enhancement extent (DE), and transmural DE pattern (TMDE) were assessed in each of the 17 left ventricular segments. Segmental functional outcome was assessed by CMR at 3 months. Logistic regression and Bayesian probabilities evaluated the association between viability indexes and functional segmental outcome. At rest, 27% of segments (314 of 1,173) were dysfunctional of which 53% (165 of 314) recovered at follow-up. Odd ratios for dobutamine response, MVO, DE, and TMDE were 15.8, 5.9, 2.6, and 2.5 respectively. The probability of segmental recovery was 0.84 when dobutamine response was positive and increased successively to 0.91 when adding MVO absence, 0.94 when adding TMDE absence, and 0.97 when adding DE absence. In conclusion, contractile response to low-dose dobutamine is the best predictive factor of segmental recovery after Thrombolysis In Myocardial Infarction grade 3 early reperfused AMI. Its value is further increased by other CMR viability indexes.
authors.affiliation: Soins Intensifs Cardiologiques--Plateau de Cardiologie Interventionnelle, France.
authors.forename: Edouard
authors.initials: E
authors.lastname: Gerbaud
authors.forename: Alexandre
authors.initials: A
authors.lastname: Faury
authors.forename: Pierre
authors.initials: P
authors.lastname: Coste
authors.forename: Matthew
authors.initials: M
authors.lastname: Erickson
authors.forename: Olivier
authors.initials: O
authors.lastname: Corneloup
authors.forename: Pierre
authors.initials: P
authors.lastname: Dos Santos
authors.forename: Catherine
authors.initials: C
authors.lastname: Durrieu-Jaïs
authors.forename: François
authors.initials: F
authors.lastname: Laurent
authors.forename: Michel
authors.initials: M
authors.lastname: Montaudon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D002316:Cardiotonic Agents; D015331:Cohort Studies; D004280:Dobutamine; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D011237:Predictive Value of Tests; D020127:Recovery of Function / Q000502:physiology*; D012720:Severity of Illness Index; D013318:Stroke Volume / Q000502:physiology; D014022:Tissue Survival / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D002316:Cardiotonic Agents; D004280:Dobutamine